Year archive

Medivir — 2015 filings

All 70 regulatory filings released by Medivir (MVIR) in 2015, sourced directly from the official regulator.

70 Filings

2015 Period

2015 filings (70)

Filing	Released	Lang
Medivir meddelar att Janssen avslutat utvecklingen av polymerashämmaren AL-704 för behandling av hepatit C Legal Proceedings Report	2015-12-21	Swedish
Medivir announces that development of the HCV nucleotide polymerase inhibitor AL-704 was terminated by Janssen Regulatory Filings	2015-12-21	English
Interim / Quarterly Report 2015 Interim / Quarterly Report Q1 2015	2015-11-20	Swedish
Interim / Quarterly Report 2015 Interim / Quarterly Report Q3 2015	2015-11-20	English
Medivir terminates the ADAM8 inhibitor project for pancreatic cancer Regulatory Filings	2015-11-17	English
Medivir avslutar projektet med ADAM8-hämmare mot bukspottkörtelcancer Regulatory Filings	2015-11-17	Swedish
Medivir announces that Janssen has started a phase IIa study to evaluate the effect of simeprevir in combination with odalasvir and AL-335 Regulatory Filings	2015-10-16	English
Medivir meddelar att Janssen har påbörjat en fas IIa-studie för att utvärdera effekten av simeprevir i kombination med odalasvir och AL-335 Regulatory Filings	2015-10-16	Swedish
OLYSIO® sales during the third quarter 2015 Earnings Release Q3 2015	2015-10-13	English
Försäljning för OLYSIO® under tredje kvartalet 2015 Earnings Release Q3 2015	2015-10-13	Swedish
Major Shareholding Notification 2015 Major Shareholding Notification	2015-09-08	English
Major Shareholding Notification 2015 Major Shareholding Notification	2015-08-27	English
Interim / Quarterly Report 2015 Interim / Quarterly Report H1 2015	2015-08-20	Swedish
Interim / Quarterly Report 2015 Interim / Quarterly Report H1 2015	2015-08-20	English
Medivir announces that Janssen has started a phase I study to evaluate the effect of simeprevir and odalasvir on AL-335 pharmacokinetics Regulatory Filings	2015-08-03	English
Medivir tillkännager att Janssen har startat en fas I-studie för att utvärdera effekten av simeprevir och odalasvir på AL-335:s farmakokinetik Regulatory Filings	2015-08-03	Swedish
Medivir meddelar start av en klinisk fas I-studie med polymerashämmaren AL-704 för behandling av hepatit C Regulatory Filings	2015-07-29	Swedish
Medivir announces start of a phase I clinical trial of the nucleotide polymerase inhibitor AL-704 for treatment of hepatitis C Regulatory Filings	2015-07-29	English
Medivir announces that Janssen submitted supplemental New Drug Application to U.S. FDA for OLYSIO® (simeprevir) in combination with sofosbuvir Regulatory Filings	2015-07-24	English
Medivir meddelar att Janssen lämnat in kompletterande registrerings-ansökan för OLYSIO® (simeprevir) i kombination med sofosbuvir till FDA i USA Regulatory Filings	2015-07-24	Swedish
OLYSIO® sales during the second quarter 2015 Earnings Release Q2 2015	2015-07-14	English
Försäljning för OLYSIO® under andra kvartalet 2015 Earnings Release Q2 2015	2015-07-14	Swedish
Medivir offentliggör första cancerprojektet från den interna nukleotidplattformen Regulatory Filings	2015-06-30	Swedish
Medivir announces the first cancer project derived from its in-house nucleotide platform Regulatory Filings	2015-06-30	English
Ökat fokus inom Medivirs F&U och optimering av resurser genom samarbete med GVK BIO Regulatory Filings	2015-06-16	Swedish
Increased focus within Medivir’s R&D and optimizing resources through a partnership with GVK BIO Board/Management Information	2015-06-16	English
Medivir’s CEO increases his shareholding in the company Director's Dealing	2015-05-12	English
Medivirs vd ökar sitt aktieinnehav i bolaget Director's Dealing	2015-05-12	Swedish
Medivir’s board of directors has resolved to repurchase own shares Transaction in Own Shares	2015-05-06	English
Medivirs styrelse har beslutat om återköp av egna aktier Transaction in Own Shares	2015-05-06	Swedish
Resolutions at the annual general meeting in Medivir on 5 May 2015 AGM Information	2015-05-05	English
Beslut vid årsstämma i Medivir den 5 maj 2015 AGM Information	2015-05-05	Swedish
Interim / Quarterly Report 2015 Interim / Quarterly Report Q1 2015	2015-05-05	Swedish
Interim / Quarterly Report 2015 Interim / Quarterly Report Q1 2015	2015-05-05	English
Positive preclinical antiviral and safety profile of MIV-802 supports continued development Regulatory Filings	2015-04-23	English
Lovande preklinisk profil för MIV-802 avseende antiviral effekt och säkerhet ger stöd för fortsatt utveckling Regulatory Filings	2015-04-23	Swedish
OLYSIO® sales during the first quarter 2015 Earnings Release Q1 2015	2015-04-14	English
Försäljning för OLYSIO under första kvartalet 2015 Earnings Release Q1 2015	2015-04-14	Swedish
Medivir och Cancer Research Technology inleder samarbete för att utveckla en ny klass av cancerläkemedel Regulatory Filings	2015-04-13	Swedish
Medivir and Cancer Research Technology collaborate to develop new class of cancer drugs Regulatory Filings	2015-04-13	English
New simeprevir data will be presented at The International Liver Congress 2015 of the European Association for the Study of the Liver (EASL) Regulatory Filings	2015-04-08	English
Nya data för simeprevir kommer att presenteras vid EASL:s ”International Liver Congress 2015” Investor Presentation	2015-04-08	Swedish
Annual Report 2014 Annual Report FY 2014	2015-04-07	Swedish
Annual Report 2014 Annual Report FY 2014	2015-04-07	English
Kallelse till årsstämma i Medivir AB (publ) AGM Information	2015-04-01	Swedish
Notice of Annual General Meeting of Medivir AB (publ) AGM Information	2015-04-01	English
Number of shares and votes in Medivir Share Issue/Capital Change	2015-03-31	English
Antalet aktier och röster i Medivir Share Issue/Capital Change	2015-03-31	Swedish
New data on Simeprevir presented at the Conference of the Asian Pacific Association for the Study of the Liver Regulatory Filings	2015-03-16	English
Nya data för Simeprevir presenterades vid Conference of the Asian Pacific Association for the Study of the Liver Earnings Release FY 2015	2015-03-16	Swedish
Medivir Capital Markets Meeting on 26 March 2015 Report Publication Announcement	2015-03-12	English
Medivir anordnar kapitalmarknadsmöte den 26 mars 2015 Regulatory Filings	2015-03-12	Swedish
Nyanställda i Medivirs ledningsgrupp Board/Management Information	2015-03-02	Swedish
New members of Medivir’s management group Board/Management Information	2015-03-02	English
Redovisning av utfallet i Medivirs frivilliga inlösenprogram Transaction in Own Shares	2015-02-27	Swedish
Presentation of the result of Medivir’s voluntary redemption programme Share Issue/Capital Change	2015-02-27	English
Earnings Release 2014 Earnings Release FY 2014	2015-02-27	Swedish
Earnings Release 2014 Earnings Release Q4 2014	2015-02-27	English
Major Shareholding Notification 2015 Major Shareholding Notification	2015-02-18	English
Medivir’s Nomination Committee proposes new Board of Directors ahead of 2015 AGM Board/Management Information	2015-02-18	English
Valberedningens förslag till ny styrelse inför årsstämman 2015 Board/Management Information	2015-02-18	Swedish
Major Shareholding Notification 2015 Major Shareholding Notification	2015-02-12	English
Final terms for Medivir’s voluntary redemption programme Share Issue/Capital Change	2015-01-30	English
Villkoren för frivilligt inlösenprogram i Medivir fastställda Delisting Announcement	2015-01-30	Swedish
Medivirs vd ökar sitt aktieinnehav i bolaget Director's Dealing	2015-01-27	Swedish
Medivir’s CEO increases his shareholding in the company Board/Management Information	2015-01-27	English
Medivir makes change within the management team Board/Management Information	2015-01-21	English
Medivir genomför förändring av ledningsgruppen Board/Management Information	2015-01-21	Swedish
OLYSIO® sales during the fourth quarter 2014 Earnings Release Q4 2014	2015-01-20	English
OLYSIO® försäljning under fjärde kvartalet 2014 Earnings Release Q4 2014	2015-01-20	Swedish

Filings by year

2026 19 filings
2025 39 filings
2024 32 filings
2023 33 filings
2022 15 filings
2021 52 filings
2020 28 filings
2019 19 filings
2018 57 filings
2017 52 filings
2016 59 filings
2015 70 filings
2014 76 filings
2013 93 filings
2012 51 filings
2011 79 filings
2010 78 filings
2009 45 filings
2008 40 filings
2007 26 filings